STEVANATO GROUP SPA (STVN) Stock Fundamental Analysis

NYSE:STVN • IT0005452658

15.52 USD
+0.21 (+1.37%)
Last: Feb 27, 2026, 08:04 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to STVN. STVN was compared to 58 industry peers in the Life Sciences Tools & Services industry. While STVN belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. STVN is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • STVN had positive earnings in the past year.
  • STVN had a positive operating cash flow in the past year.
  • STVN had positive earnings in each of the past 5 years.
  • STVN had a positive operating cash flow in each of the past 5 years.
STVN Yearly Net Income VS EBIT VS OCF VS FCFSTVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M -300M

1.2 Ratios

  • The Return On Assets of STVN (5.81%) is better than 81.03% of its industry peers.
  • Looking at the Return On Equity, with a value of 9.76%, STVN is in the better half of the industry, outperforming 79.31% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 8.02%, STVN belongs to the best of the industry, outperforming 82.76% of the companies in the same industry.
  • STVN had an Average Return On Invested Capital over the past 3 years of 9.71%. This is below the industry average of 11.97%.
Industry RankSector Rank
ROA 5.81%
ROE 9.76%
ROIC 8.02%
ROA(3y)6.9%
ROA(5y)7.65%
ROE(3y)11.86%
ROE(5y)15.36%
ROIC(3y)9.71%
ROIC(5y)10.46%
STVN Yearly ROA, ROE, ROICSTVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

  • STVN's Profit Margin of 11.99% is amongst the best of the industry. STVN outperforms 81.03% of its industry peers.
  • STVN's Profit Margin has improved in the last couple of years.
  • Looking at the Operating Margin, with a value of 17.74%, STVN belongs to the top of the industry, outperforming 81.03% of the companies in the same industry.
  • In the last couple of years the Operating Margin of STVN has grown nicely.
  • STVN's Gross Margin of 29.27% is on the low side compared to the rest of the industry. STVN is outperformed by 75.86% of its industry peers.
  • STVN's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 17.74%
PM (TTM) 11.99%
GM 29.27%
OM growth 3Y-5.27%
OM growth 5Y7.16%
PM growth 3Y-12.48%
PM growth 5Y7.86%
GM growth 3Y-3.05%
GM growth 5Y2.24%
STVN Yearly Profit, Operating, Gross MarginsSTVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 10 20 30

4

2. Health

2.1 Basic Checks

  • STVN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • STVN has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, STVN has less shares outstanding
  • Compared to 1 year ago, STVN has an improved debt to assets ratio.
STVN Yearly Shares OutstandingSTVN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
STVN Yearly Total Debt VS Total AssetsSTVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 4.21 indicates that STVN is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.21, STVN belongs to the top of the industry, outperforming 81.03% of the companies in the same industry.
  • STVN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.26, STVN is in line with its industry, outperforming 51.72% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z 4.21
ROIC/WACC0.9
WACC8.89%
STVN Yearly LT Debt VS Equity VS FCFSTVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • STVN has a Current Ratio of 1.89. This is a normal value and indicates that STVN is financially healthy and should not expect problems in meeting its short term obligations.
  • STVN has a worse Current ratio (1.89) than 63.79% of its industry peers.
  • A Quick Ratio of 1.30 indicates that STVN should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.30, STVN is doing worse than 70.69% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.3
STVN Yearly Current Assets VS Current LiabilitesSTVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

6

3. Growth

3.1 Past

  • STVN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.89%, which is quite good.
  • Measured over the past years, STVN shows a very strong growth in Earnings Per Share. The EPS has been growing by 27.29% on average per year.
  • Looking at the last year, STVN shows a small growth in Revenue. The Revenue has grown by 6.98% in the last year.
  • Measured over the past years, STVN shows a quite strong growth in Revenue. The Revenue has been growing by 15.53% on average per year.
EPS 1Y (TTM)14.89%
EPS 3Y-6.42%
EPS 5Y27.29%
EPS Q2Q%16.67%
Revenue 1Y (TTM)6.98%
Revenue growth 3Y9.37%
Revenue growth 5Y15.53%
Sales Q2Q%9.12%

3.2 Future

  • Based on estimates for the next years, STVN will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.99% on average per year.
  • The Revenue is expected to grow by 8.20% on average over the next years. This is quite good.
EPS Next Y11.64%
EPS Next 2Y16.12%
EPS Next 3Y19.33%
EPS Next 5Y17.99%
Revenue Next Year7.07%
Revenue Next 2Y8.33%
Revenue Next 3Y9%
Revenue Next 5Y8.2%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
STVN Yearly Revenue VS EstimatesSTVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
STVN Yearly EPS VS EstimatesSTVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 0.2 0.4 0.6 0.8 1

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 24.25, which indicates a rather expensive current valuation of STVN.
  • Based on the Price/Earnings ratio, STVN is valued a bit cheaper than 75.86% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of STVN to the average of the S&P500 Index (27.10), we can say STVN is valued inline with the index average.
  • STVN is valuated rather expensively with a Price/Forward Earnings ratio of 20.30.
  • Based on the Price/Forward Earnings ratio, STVN is valued a bit cheaper than the industry average as 79.31% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 28.06. STVN is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 24.25
Fwd PE 20.3
STVN Price Earnings VS Forward Price EarningsSTVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, STVN is valued cheaper than 86.21% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 14.63
STVN Per share dataSTVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4 5

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates STVN does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of STVN may justify a higher PE ratio.
  • A more expensive valuation may be justified as STVN's earnings are expected to grow with 19.33% in the coming years.
PEG (NY)2.08
PEG (5Y)0.89
EPS Next 2Y16.12%
EPS Next 3Y19.33%

3

5. Dividend

5.1 Amount

  • STVN has a yearly dividend return of 0.39%, which is pretty low.
  • In the last 3 months the price of STVN has falen by -33.56%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • Compared to an average industry Dividend Yield of 0.10, STVN pays a better dividend. On top of this STVN pays more dividend than 87.93% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.80, STVN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.39%

5.2 History

  • STVN has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
STVN Yearly Dividends per shareSTVN Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 0.02 0.04 0.06 0.08

5.3 Sustainability

  • 10.83% of the earnings are spent on dividend by STVN. This is a low number and sustainable payout ratio.
DP10.83%
EPS Next 2Y16.12%
EPS Next 3Y19.33%
STVN Yearly Income VS Free CF VS DividendSTVN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M
STVN Dividend Payout.STVN Dividend Payout, showing the Payout Ratio.STVN Dividend Payout.PayoutRetained Earnings

STEVANATO GROUP SPA

NYSE:STVN (2/27/2026, 8:04:00 PM)

15.52

+0.21 (+1.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06
Earnings (Next)03-05
Inst Owners110.43%
Inst Owner Change-7.46%
Ins Owners1.61%
Ins Owner ChangeN/A
Market Cap4.70B
Revenue(TTM)1.17B
Net Income(TTM)140.28M
Analysts83.53
Price Target29.57 (90.53%)
Short Float %4.61%
Short Ratio3.91
Dividend
Industry RankSector Rank
Dividend Yield 0.39%
Yearly Dividend0.06
Dividend Growth(5Y)N/A
DP10.83%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.7%
Min EPS beat(2)2.71%
Max EPS beat(2)10.69%
EPS beat(4)4
Avg EPS beat(4)6.2%
Min EPS beat(4)1.13%
Max EPS beat(4)10.69%
EPS beat(8)4
Avg EPS beat(8)-3.95%
EPS beat(12)6
Avg EPS beat(12)-2.39%
EPS beat(16)10
Avg EPS beat(16)0.56%
Revenue beat(2)2
Avg Revenue beat(2)2.35%
Min Revenue beat(2)2.33%
Max Revenue beat(2)2.36%
Revenue beat(4)4
Avg Revenue beat(4)1.76%
Min Revenue beat(4)0.62%
Max Revenue beat(4)2.36%
Revenue beat(8)4
Avg Revenue beat(8)0%
Revenue beat(12)5
Avg Revenue beat(12)-0.02%
Revenue beat(16)7
Avg Revenue beat(16)-0.03%
PT rev (1m)0%
PT rev (3m)-0.38%
EPS NQ rev (1m)-0.59%
EPS NQ rev (3m)-4.64%
EPS NY rev (1m)0%
EPS NY rev (3m)0.1%
Revenue NQ rev (1m)-0.27%
Revenue NQ rev (3m)-1.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.08%
Valuation
Industry RankSector Rank
PE 24.25
Fwd PE 20.3
P/S 3.4
P/FCF N/A
P/OCF 16.88
P/B 2.77
P/tB 2.94
EV/EBITDA 14.63
EPS(TTM)0.64
EY4.12%
EPS(NY)0.76
Fwd EY4.93%
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)0.92
OCFY5.93%
SpS4.57
BVpS5.61
TBVpS5.28
PEG (NY)2.08
PEG (5Y)0.89
Graham Number8.99
Profitability
Industry RankSector Rank
ROA 5.81%
ROE 9.76%
ROCE 10.67%
ROIC 8.02%
ROICexc 8.51%
ROICexgc 8.92%
OM 17.74%
PM (TTM) 11.99%
GM 29.27%
FCFM N/A
ROA(3y)6.9%
ROA(5y)7.65%
ROE(3y)11.86%
ROE(5y)15.36%
ROIC(3y)9.71%
ROIC(5y)10.46%
ROICexc(3y)11.09%
ROICexc(5y)13.59%
ROICexgc(3y)11.88%
ROICexgc(5y)15.21%
ROCE(3y)13.31%
ROCE(5y)14.16%
ROICexgc growth 3Y-28.59%
ROICexgc growth 5Y-6.94%
ROICexc growth 3Y-26.56%
ROICexc growth 5Y-4.42%
OM growth 3Y-5.27%
OM growth 5Y7.16%
PM growth 3Y-12.48%
PM growth 5Y7.86%
GM growth 3Y-3.05%
GM growth 5Y2.24%
F-Score6
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA 1.26
Cap/Depr 325.28%
Cap/Sales 23.24%
Interest Coverage 24.33
Cash Conversion 80.94%
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.3
Altman-Z 4.21
F-Score6
WACC8.89%
ROIC/WACC0.9
Cap/Depr(3y)442.35%
Cap/Depr(5y)341.04%
Cap/Sales(3y)31.28%
Cap/Sales(5y)24.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.89%
EPS 3Y-6.42%
EPS 5Y27.29%
EPS Q2Q%16.67%
EPS Next Y11.64%
EPS Next 2Y16.12%
EPS Next 3Y19.33%
EPS Next 5Y17.99%
Revenue 1Y (TTM)6.98%
Revenue growth 3Y9.37%
Revenue growth 5Y15.53%
Sales Q2Q%9.12%
Revenue Next Year7.07%
Revenue Next 2Y8.33%
Revenue Next 3Y9%
Revenue Next 5Y8.2%
EBIT growth 1Y17.7%
EBIT growth 3Y3.61%
EBIT growth 5Y23.8%
EBIT Next Year69.76%
EBIT Next 3Y33.44%
EBIT Next 5Y24.25%
FCF growth 1Y86.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.37%
OCF growth 3Y5.33%
OCF growth 5Y29.6%

STEVANATO GROUP SPA / STVN FAQ

What is the ChartMill fundamental rating of STEVANATO GROUP SPA (STVN) stock?

ChartMill assigns a fundamental rating of 5 / 10 to STVN.


What is the valuation status of STEVANATO GROUP SPA (STVN) stock?

ChartMill assigns a valuation rating of 4 / 10 to STEVANATO GROUP SPA (STVN). This can be considered as Fairly Valued.


How profitable is STEVANATO GROUP SPA (STVN) stock?

STEVANATO GROUP SPA (STVN) has a profitability rating of 7 / 10.


Can you provide the financial health for STVN stock?

The financial health rating of STEVANATO GROUP SPA (STVN) is 4 / 10.


Can you provide the dividend sustainability for STVN stock?

The dividend rating of STEVANATO GROUP SPA (STVN) is 3 / 10 and the dividend payout ratio is 10.83%.